3656 results for «600»
3656 results
Challenges in treating tricuspid regurgitation
22 May 2026 – From EuroPCR 2026
This session addresses the complexities of treating tricuspid regurgitation, offering insights into tailored treatment options and complication management. Through detailed case studies from China and Germany, it highlights practical approaches and bailout strategies for tricuspid valve interventions.
TAVI in bicuspid - Planning to performance
22 May 2026 – From EuroPCR 2026
Dedicated to transcatheter aortic valve implantation (TAVI) in bicuspid aortic valves, this session examines anatomical assessment, sizing methods, and clinical outcomes. It includes meta-analyses and registry insights, addressing challenges such as stent deformation and leaflet modification to guide optimal TAVI performance in this distinct patient population.
How to treat aortic regurgitation
22 May 2026 – From EuroPCR 2026
Explore cutting-edge transcatheter approaches for aortic regurgitation, including first-in-human ATLAS technique, management in LVAD patients, and off-label Myval use. This session reviews clinical challenges and innovative solutions in aortic valve interventions, offering valuable insights from complex procedural experiences.
Left main complications - Part 3
21 May 2026 – From EuroPCR 2026
This session reviews complex complications encountered in left main coronary interventions. It covers causes and management of acute left main occlusion, critical stenosis of coronary buttons, retrieval techniques for ostial stents, and strategies for managing challenging PCI scenarios that may precipitate or resolve catastrophic events.
Left main PCI, what is known and what is new
21 May 2026 – From EuroPCR 2026
This session examines both established knowledge and novel advances in left main PCI. Topics include the use of novel stents and laser atherectomy in calcified lesions, the prognostic impact of cardiac motion during bifurcation PCI, effects of left ventricular dysfunction, and sex-specific survival outcomes, as well...
Left main PCI: predictions of risk and long-term clinical outcome
22 May 2026 – From EuroPCR 2026
This session focuses on risk prediction and long-term outcomes following left main percutaneous coronary intervention (PCI). It covers biomarkers like NT-proBNP, hemodynamic predictors, and the impact of comorbidities such as diabetes and chronic kidney disease on patient prognosis over a ten-year follow-up.
Multivessel disease or left main disease
22 May 2026 – From EuroPCR 2026
This session explores revascularisation strategies for patients with multivessel or left main coronary artery disease. It emphasizes the role of intravascular physiology and imaging in guiding treatment decisions and highlights procedural factors that contribute to improved long-term clinical outcomes, supported by complex case discussions.
TAVI interventions for all? From congenital bicuspid valve towards valve-in-valve challenging cases
21 May 2026 – From EuroPCR 2026
This session delves into the complexities of TAVI interventions across diverse challenging cases, including congenital bicuspid valves and valve-in-valve scenarios. It emphasizes complication prevention, decision-making for the Unicorn technique, and the critical role of pre-procedural imaging, illustrated through detailed case studies from Estonia, the Netherlands, and...
When atrial septal closure gets complex
21 May 2026 – From EuroPCR 2026
This session explores the complexities that arise when atrial septal closure procedures become challenging. It covers hybrid retrieval techniques for occluder devices, management of device-related complications mimicking infection, resolution of uncommon complications, and case studies including cryptogenic stroke management in athletes, highlighting procedural intricacies and solutions.
STEMI management around the world
21 May 2026 – From EuroPCR 2026
This session presents a global perspective on STEMI management, addressing strategies to reduce reperfusion delays through nurse-integrated pathways and comparing intracoronary versus intravenous Tirofiban use during primary PCI. It includes epidemiological insights from Rwanda and Egypt, evaluates thrombo-aspiration practices in Sub-Saharan Africa, and examines outcomes in...
Primary Outcomes of a Pivotal Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Ballon with Conventional Ballon Angioplasty for In-Stent Restenosis (AGENT IDE)
27 Oct 2023
Mirvat Alasnag provides her take on the AGENT IDE trial which was presented by Robert W. Yeh at TCT Congress 2023. This pivotal randomized trial compares the safety and efficacy of the AGENT DCB to conventional balloon angioplasty in patients with ISR. It is the first...
Author
The greatest advance in the next 40 years would be to remove the need for angioplasty
17 May 2017
Spencer B. King performed some of the first coronary angioplasty procedures in the USA—having recently received a thank-you from the first patient that he treated. He tells The Daily Wire that the steerable guidewire, rather than the stent, was the greatest advance in angioplasty and that...
Authors :
ALL-RISE: A large-scale, global randomized trial of coronary physiology derived from conventional angiography compared with an invasive pressure wire-based approach to guide PCI
28 Mar 2026
Mirvat Al Asnag provides her take on the ALL-RISE randomised trial presented by Ajay J. Kirtane at ACC.26 in New Orleans.
Author
COVID-19 vaccines: Burning questions from the community and real-world applicability
13 Jan 2021
View a number of questions of interest to the interventional cardiovascular community, as well as the real-world applicability of COVID-19 vaccine trials.
The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation
01 Sep 2025
Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.
Author
![The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]](https://www.pcronline.com/var/pcrov3/storage/images/pcronline/news/congress-coverages/esc/2025/aquatic-trial-quitting-versus-using-aspirin-therapy-patients-stabilized-cad-stenting-long-term-oral-anticoagulation/27448089-9-eng-GB/The-AQUATIC-trial-Assessment-of-quitting-versus-using-aspirin-therapy-in-patients-with-stabilized-coronary-artery-disease-after-stenting-who-requi_image_responsive_6.jpg)
A randomized, placebo-controlled trial of chronic total occlusion PCI in stable angina - ORBITA-CTO trial
03 Apr 2026
Kalaivani Mahadevan provides an in-depth analysis of the ORBITA-CTO trial: a first-ever randomised, double-blind, placebo-controlled trial evaluating CTO PCI in stable angina patients.
She also interviewed principal investigators Sarosh Khan and John Davies following the LBCT Scientific Session at ACC.26 in New Orleans and simultaneous publication in...
Author
Author
Author
